AI Applied to Tangential Flow Filtration
Advanced digital applications are being increasingly applied to Tangential Flow Filtration (TFF) systems, according to a recent Biomanufacturing & Fermentation Technology podcast. Experts highlighted the use of machine learning models to predict membrane fouling events and optimize cleaning cycles in industrial fermentation. This data-driven approach aims to improve process robustness, yield consistency, and compliance in a critical unit operation for biologics manufacturing.
- In viral vector manufacturing, Tangential Flow Filtration (TFF) is crucial for purification but faces challenges in scalability; linearly scaling membrane size may not be commercially feasible, sometimes requiring the use of slightly undersized membranes with longer processing times to maintain consistent flow rates. - The application of AI in downstream processing, which can account for about 60% of biologic drug production costs, has lagged behind upstream applications. However, hybrid models combining mass transfer theory with machine learning are being developed to improve the predictability of TFF processes, which can be variable depending on factors like membrane size and DNA concentration. - Digital twins are being created for biomanufacturing processes, including those for recombinant adeno-associated virus (rAAV) production, to validate scaling principles and optimize processes by simulating the transition from lab-scale to industrial-scale bioreactors. These virtual replicas use real-time data to monitor and predict outcomes, which helps to mitigate risks associated with scaling up. - Electronic Batch Records (EBRs) are critical for data integrity in GMP environments, with a single cell and gene therapy batch record containing upwards of 3,000 data points. Failures in batch record-keeping were cited in 42% of FDA warning letters to pharmaceutical facilities between 2020-2023, highlighting the importance of robust digital systems. - The Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is projected to grow significantly, with one forecast predicting an expansion from $8.07 billion in 2025 to around $74.03 billion by 2034, a CAGR of 27.92%. This growth is driven by the increasing demand for outsourced manufacturing and regulatory expertise. - Transitioning from a senior scientist to a director or executive role in biotech often leads to a 25-40% salary increase within two years of the promotion. The move requires a shift from hands-on lab work to focusing on strategy, resource allocation, and team development. - For scientists moving into leadership, developing strong communication skills is essential for articulating project goals and outcomes to both scientific and non-scientific audiences, a key responsibility for executive roles like Director, VP, or CSO. - Leaders transitioning from R&D to executive positions in biotech often face challenges with the shift from a controlled laboratory environment to making strategic decisions with incomplete information. Many executives in this space are scientists by training who have never led a company before.
